Na v 1.7 as a chondrocyte regulator and therapeutic target for osteoarthritis
Wenyu Fu,Dmytro Vasylyev,Yufei Bi,Mingshuang Zhang,Guodong Sun,Asya Khleborodova,Guiwu Huang,Libo Zhao,Renpeng Zhou,Yonggang Li,Shujun Liu,Xianyi Cai,Wenjun He,Min Cui,Xiangli Zhao,Aubryanna Hettinghouse,Julia Good,Ellen Kim,Eric Strauss,Philipp Leucht,Ran Schwarzkopf,Edward X. Guo,Jonathan Samuels,Wenhuo Hu,Mukundan Attur,Stephen G. Waxman,Chuan-ju Liu
DOI: https://doi.org/10.1038/s41586-023-06888-7
IF: 64.8
2024-01-04
Nature
Abstract:Osteoarthritis (OA) is the most common joint disease. Currently there are no effective methods that simultaneously prevent joint degeneration and reduce pain 1 . Although limited evidence suggests the existence of voltage-gated sodium channels (VGSCs) in chondrocytes 2 , their expression and function in chondrocytes and in OA remain essentially unknown. Here we identify Na v 1.7 as an OA-associated VGSC and demonstrate that human OA chondrocytes express functional Na v 1.7 channels, with a density of 0.1 to 0.15 channels per μm 2 and 350 to 525 channels per cell. Serial genetic ablation of Na v 1.7 in multiple mouse models demonstrates that Na v 1.7 expressed in dorsal root ganglia neurons is involved in pain, whereas Na v 1.7 in chondrocytes regulates OA progression. Pharmacological blockade of Na v 1.7 with selective or clinically used pan-Na v channel blockers significantly ameliorates the progression of structural joint damage, and reduces OA pain behaviour. Mechanistically, Na v 1.7 blockers regulate intracellular Ca 2+ signalling and the chondrocyte secretome, which in turn affects chondrocyte biology and OA progression. Identification of Na v 1.7 as a novel chondrocyte-expressed, OA-associated channel uncovers a dual target for the development of disease-modifying and non-opioid pain relief treatment for OA.
multidisciplinary sciences